Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.

Indian firm Centaur confirms to Scrip that a planned alliance with Santen for the Indian market is not going ahead, as the mid-sized Japanese ophthalmic specialist says it is looking to build up its direct presence in Asia.

Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.

Japan’s Santen appears set for a scale up in India via an alliance with Centaur Pharmaceuticals. The partners outline to Scrip the broad contours of the India plan.